News
PAVM
1.339
-16.57%
-0.266
*Lucid Diagnostics 3Q EBITDA Loss $6.5M >LUCD
Dow Jones · 11h ago
*Lucid Diagnostics 3Q Rev $1.2M >LUCD
Dow Jones · 11h ago
*Lucid Diagnostics 3Q Loss/Shr 3c >LUCD
Dow Jones · 11h ago
Press Release: Lucid Diagnostics Provides -2-
Dow Jones · 12h ago
Weekly Report: what happened at PAVM last week (1102-1106)?
Weekly Report · 3d ago
Earnings Week Ahead: CSCO, CRWV, PLUG, ALC, AMAT, ACB, RKLB, ASTS, and more
Seeking Alpha · 4d ago
PAVmed Unit Lucid Diagnostics Announces Publication Of Clinical Findings From Nonendoscopic Esophageal Precancer Testing Using The EsoGuard; Study Demonstrates Efficiency And Scalability Of EsoCheckCell Collection In Under Two Minutes
Benzinga · 11/03 13:17
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 11/03 12:05
Weekly Report: what happened at PAVM last week (1026-1030)?
Weekly Report · 11/02 09:48
Weekly Report: what happened at PAVM last week (1019-1023)?
Weekly Report · 10/26 09:47
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 10/23 12:05
Why RingCentral Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket
Benzinga · 10/23 08:34
PAVmed Inc. Subsidiary Lucid Diagnostics Raises $15.0 million in Series C Preferred Stock Offering
NASDAQ · 10/23 03:18
Lucid Shares Jump 40% Overnight On EsoGuard Medicare Payments, $15 Mln Financing
NASDAQ · 10/23 03:14
PAVmed Subsidiary Lucid Diagnostics Completes Preferred Financing
TipRanks · 10/22 21:44
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 10/22 21:05
Lucid Diagnostics Receiving Medicare Payments For Its EsoGuard Esophageal DNA Test; Closed $15M Private Placement Of Its Newly Designated Series C Convertible Prefs To Existing Long-Term Shareholders On October 21
Benzinga · 10/22 20:28
Lucid Diagnostics begins receiving Medicare reimbursement for EsoGuard
TipRanks · 10/22 20:25
Weekly Report: what happened at PAVM last week (1012-1016)?
Weekly Report · 10/19 09:47
Weekly Report: what happened at PAVM last week (1005-1009)?
Weekly Report · 10/12 09:51
More
Webull provides a variety of real-time PAVM stock news. You can receive the latest news about Pavmed through multiple platforms. This information may help you make smarter investment decisions.
About PAVM
PAVmed Inc. is a multi-product, commercial-stage medical technology company. The Company operates in the medical devices, diagnostics, and digital health sectors. Its subsidiary includes Lucid Diagnostics Inc., which is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device for early detection of esophageal precancer to prevent esophageal cancer deaths. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. Its other subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices.